XPA Enhances Temozolomide Resistance of Glioblastoma Cells by Promoting Nucleotide Excision Repair

Glioblastoma is the most frequent, as well as aggressive kind of high-grade malignant glioma. Chemoresistance is posing a significant clinical barrier to the efficacy of temozolomide-based glioblastoma treatment. By suppressing xeroderma pigmentosum group A (XPA), a pivotal DNA damage recognition pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Weimin, Wu, An, Li, Yunping, Yu, Guofeng, Yan, Xinjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096195/
https://www.ncbi.nlm.nih.gov/pubmed/35536165
http://dx.doi.org/10.1177/09636897221092778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096195/
https://www.ncbi.nlm.nih.gov/pubmed/35536165
http://dx.doi.org/10.1177/09636897221092778

Ejemplares similares